Orforglipron (brand name: Foundayo), a once-daily pill-based weight-loss drug that targets the same GLP-1 system as Wegovy, has recently been approved by the US Food and Drug Administration for treating obesity
MOS contains high phenol and flavonoid content, which are crucial oxidative components in plants
While results in experimental models are promising, research remains preliminary, and findings are not yet conclusive for translational outcomes
By your 40s, you may have significantly less glutathione than you did in your 20s
The jump from diabetes treatment to weight management was not a change in formulation, but rather an increase in dose
If everything is dramatic but nothing is concrete, thats a problem